Pregnancy-Induced CYP450 Variability:

Implications for Personalized Maternal and Fetal Drug Safety

 

Sowmya ML, Dhivya C, Satheesh S

JKKN College of Pharmacy.

 

ABSTRACT:

Pregnancy causes major physiological alterations that influence drug metabolism, especially by the cytochrome P450 (CYP450) enzyme system. The changes result in drug pharmacokinetic variability, necessitating careful dosage adjustment to maintain maternal and fetal safety. CYP3A4 and CYP2D6 activity is increased during pregnancy, accelerating drug metabolism, whereas CYP1A2 and CYP2C19 activity is reduced, resulting in changed drug clearance. Genetic polymorphisms also regulate drug responses, affecting therapeutic efficacy and adverse effect risk. The scarcity of clinical pharmacokinetic information in pregnant populations makes it difficult to assess drug safety, requiring complementary approaches like physiologically based pharmacokinetic (PBPK) modeling, liquid biopsy technologies, and AI-driven pharmacogenomic predictions. These technologies allow for personalized dosing strategies, reducing fetal drug exposure while maximizing maternal treatment. Pharmacogenetic screening and therapeutic drug monitoring (TDM) are becoming ever more crucial for personalized medicine during pregnancy pharmacotherapy. Progress is hampered, though, by issues like the absence of a diverse set of pharmacogenomic data, gaps in regulation, and ethical limitations in clinical trials. Future research must combine genetic screening with high-tech drug monitoring methods to advance pregnancy- specific dosing algorithms. Further increases in pharmacogenomic databases, creation of improved in vitro models of the placenta, and overcoming racial genetic heterogeneity will further improve the safety of medications in pregnant women. Interdisciplinary research is key to bridging these knowledge gaps and translating pharmacogenomics to personalized pharmacotherapy in maternal-fetal medicine.

 

 

 

INTRODUCTION:

Pregnancy is a special physiological condition that is associated with profound changes in hormonal, metabolic, and hemodynamic variables, all of which may affect the pharmacokinetics of drugs¹. Plasma volume expands by about 30–50%, causing changed drug distribution, whereas renal clearance may increase by over 50% because of augmented glomerular filtration rate². In addition, hepatic enzyme activity may change, with some enzymes increasing and others decreasing activity, thus either accelerating or decelerating drug metabolism depending on the drug involved³. In light of these complexities, sophisticated pharmacokinetic models are advisable to estimate drug exposure and inform dosing. According to clinical guidelines, careful consideration of these factors is critical when prescribing medications during pregnancy to ensure both maternal and fetal safety.

 

Cytochrome P450 (CYP450) enzymes are also important in the Phase I metabolism of most drugs, where they catalyze chemical alterations like oxidation, reduction, and hydrolysis⁴. CYP450 enzymes are essential for the transformation of lipophilic substances into more hydrophilic metabolites that can easily be excreted from the body. During pregnancy, a number of CYP450 isoforms experience remarkable changes in their activity, thereby influencing drug clearance and dosing needs⁵. CYP3A4 activity is enhanced by 1.25, 1.75, and 2.32 times the non-pregnant value in the second and third trimesters of pregnancy, as reported in research by Abduljalil K et al., (2020)⁶. Likewise, CYP2D6 activity increases markedly, whereas CYP1A2 activity tends to reduce, resulting in decreased clearance of some drugs (Tracy et al., 2005)⁷. CYP2C9 activity increases from 1 to 2% of adult values in the first trimester, then rises to 30% of adult values in the second and third trimesters, and fluctuates 35-fold between birth and 5 months. (Koukouritaki SB et al, 2003)⁸. These alterations underscore the requirement for individualized drug dosing during pregnancy, backed by a knowledge of how particular CYP450 enzymes are regulated by hormonal and physiological changes.

 

The use of medicines in pregnancy poses several challenges on account of physiological alterations, variability between individuals, and fetal considerations⁹. There is scant clinical information available on drug metabolism in pregnancy since ethical considerations commonly preclude controlled studies in this group. It makes dose optimization and risk evaluation difficult. Much variability in the activity of the CYP450 enzymes has been observed in pregnant subjects in studies. CYP3A4 and CYP2D6 activities tend to rise, but the extent of this rise may be highly variable between individuals, as demonstrated by McCune JS et al. (2001)¹⁰. In contrast, Pregnancy changes drug pharmacokinetics, with a 30% increase in CYP1A2 activity and a 30% decrease in CYP2D6 activity in the third trimester, as reported by Lu, G et al., (2012)¹¹. These shifts in enzyme activity add to drug exposure variability, such that therapeutic and toxic effects cannot be predicted. In addition, the fetus is highly susceptible to xenobiotics and their metabolites because of an immature enzyme system and forming organs. Some drugs or metabolites may pass through the placenta and possibly have harmful developmental consequences. Research like that of Muanda FT et al. (2015) on antimalarial medications points to the dangers of fetal exposure to poorly understood drug metabolites¹². These issues reinforce the necessity for more stringent data collection, personalized therapy tactics, and thorough balancing of risks and benefits when contemplating drug intake during pregnancy. Recent pharmacological investigations have further emphasized the importance of pharmacokinetics, pharmacodynamics and pharmacogenomics in understanding variability in drug metabolism and optimizing personalized drug therapy^71-73.

 

CYP450 VARIABILITY IN PREGNANT WOMEN: MECHANISMS AND IMPLICATIONS:

Pregnancy-Induced CYP450 Expression Changes:

Pregnancy causes considerable changes in the expression of different cytochrome P450 (CYP) enzymes, and this affects drug metabolism that may influence both maternal and fetal well-being. Importantly, CYP3A4 and CYP2D6 activities are increased during pregnancy. For example, Zhang et al. (2008) provided evidence that hepatic Cyp3a protein expression and activity rose significantly throughout gestation in mice, hinting at such induction of CYP3A4 in the human species¹³. Other studies have identified that estradiol and progesterone, hormones that increase during pregnancy, are capable of inducing the transcription of CYP3A4 and CYP2D6 (Choi SY, 2013; Papageorgiou I et al., 2012)^14,15. This increased upregulation is able to increase drug metabolism of drugs such as some antidepressants (e.g., sertraline, fluoxetine) and antiepileptics (e.g., lamotrigine, carbamazepine), decreasing their effects. Zhang Y et al. (2024) stated that CYP3A4 expression rises step by step over trimesters, doubling the clearance rate of drugs that are metabolized by this enzyme¹⁶. Likewise, during pregnancy, CYP2D6 activity is increased, possibly through induction of the enzyme, impacting drug metabolism and possibly impacting drug safety. (Wadelius M et al., 1997)¹⁷.

 

Figure1: Pregnancy-Induced Changes in CYP450 Expression and Drug Metabolism^13-23

On the other hand, CYP1A2 and CYP2C19 expression is reduced during pregnancy, resulting in reduced metabolism of drugs like caffeine, theophylline, and proton pump inhibitors. Tracy TS et al. (2005) reported that CYP1A2 activity reduces by 65%–80% in the third trimester, which is the reason for the significantly increased caffeine clearance in pregnant patients⁷. This leads to increased plasma levels and a greater risk of toxicity from drugs metabolized by CYP1A2. Furthermore, pregnant women carrying the CYP2C19 and CYP2D6 polymorphisms present with varied responses to antidepressant treatment, of which 10% are exposed to antidepressants (Kee PS et al., 2023)¹⁹. Such alterations in enzyme expression are not homogeneous across pregnancy; instead, they show temporal variability across trimesters, thereby underlining the requirement for trimester-specific dosing adjustment for a majority of drugs. Similar pharmacological studies have reported that alterations in metabolic enzyme activity significantly influence drug response, therapeutic efficacy and safety outcomes^74,75. The balance of enzyme suppression and induction, while complex, accentuates the nature of pregnancy pharmacotherapy in necessitating optimal titration of the dose along with therapeutic monitoring to achieve the aim of maximizing safety and efficacy in both fetus and mother.

 

Genetic polymorphisms in CYP450 and maternal drug response:

Genetic polymorphisms in cytochrome P450 (CYP450) enzymes, especially CYP2D6, CYP2C9, and CYP2C19, have a significant impact on maternal drug response during pregnancy. Genetic variations may result in varying rates of drug metabolism, impacting both the efficacy and safety of drugs given to pregnant patients.

 

CYP2d6 polymorphisms and opioid metabolism:

CYP2D6 genotype influences the pharmacokinetics of the opioids, poor metabolizers requiring alternative analgesics or a reduced dose, and ultra-rapid metabolizers requiring alternative medication or a 40% reduction in dose²⁰. Genetic polymorphisms of the CYP2D6 gene cause different enzyme activities resulting in different metabolizer phenotypes:

·       Ultrarapid Metabolizers (UMs): Patients with two copies of active CYP2D6 alleles have higher enzyme activity. The increased activity results in the quick conversion of prodrugs such as codeine to their active metabolites (e.g., morphine), which causes increased drug levels above expectations and enhanced risk of toxicity, including respiratory depression. The Clinical Pharmacogenetics Implementation Consortium (CPIC) advises against the use of codeine in UMs because of the risk of serious toxicity²¹.

·       Poor Metabolizers (PMs): Those with nonfunctional CYP2D6 alleles possess decreased or no enzyme function, resulting in poor conversion of prodrugs to their active metabolites. This may create insufficient pain alleviation when certain drugs such as codeine or tramadol are used. In accordance with CPIC recommendations, other analgesics not catabolized by CYP2D6 should be contemplated for PMs to ensure sufficient pain relief²².

 

During pregnancy, CYP2D6 activity is increased, which can also affect drug metabolism. Maternal CYP2D6 phenotype has a significant effect on foetal morphine exposure, with the highest risk being in the first trimester for CYP2D6 UM phenotype mothers, suggesting that the highest risk with regard to fetal morphine exposure is in the first trimester of pregnancy²³.

 

CYP2C9 and CYP2C19 Polymorphisms in Anticoagulants and Antidepressants:

CYP2C9 and CYP2C19 enzyme polymorphisms influence the metabolism of anticoagulants and antidepressants, with variants of CYP2C9 leading to extreme bleeding events and phenytoin toxicity.

·       CYP2C9: Genetic polymorphisms in the CYP2C9 gene have the potential to influence warfarin metabolism, a popular anticoagulant medication. People with some CYP2C9 variants have a possibility of slower warfarin metabolism, hence the risk of bleeding associated with it. Genotyping for CYP2C9 variants thus can guide the right dosage of warfarin to ensure maximum therapeutic effects²⁴.

·    CYP2C19: Metabolizes various antidepressants such as selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram. Genetic polymorphisms result in differences in enzyme activity:

 

Ultrarapid Metabolizers (UMs): Those with higher CYP2C19 activity can quickly metabolize SSRIs, potentially leading to below-therapeutic drug concentrations and decreased antidepressant response. According to Jukić et al. (2017), Patients who carry the CYP2C19*17 allele exhibit ultrarapid metabolism of escitalopram with 24.8% lower serum concentrations (Bråten LS et al., 2021)²⁵.

 

Poor Metabolizers (PMs): Individuals with reduced CYP2C19 activity can have higher drug concentrations, and therefore, their risk for adverse effects will be higher. The same study found escitalopram serum concentrations to be substantially higher in CYP2C19 PMs, which can cause dose-related side effects.

 

Table 1: Pharmacogenetics and Drug Metabolism in Pregnancy and Disease

Year	Authors	Enzyme(s) Studied	Drug(s) Studied	Population Studied	Key Findings
2022	J. Qin et al.	CYP450 (General)	Ovulatory drugs, antidepressants, antiabortifacients, and traditional Chinese medicines	Chinese Population	Maternal drug use combined with CYP450 polymorphisms may increase congenital heart defect risk in offspring26.
2014	Aizati N.A. Daud et al.	Placental Transporter Proteins	Drug-induced birth defects	General Population	Polymorphisms in placental transporter proteins may influence fetal drug exposure and congenital birth defect risks27.
2020	A. Shea et al.	CYP450	SSRIs, SNRIs	Pregnant Women and Neonates	Maternal CYP polymorphisms do not significantly affect the rate of neonatal abstinence syndrome following in utero SSRI/SNRI exposure28.
2024	Oluwasegun Eniaiyewu et al.	CYP2B6	Efavirenz	Pregnant Women	Maternal CYP2B6 genotype influences efavirenz plasma levels, while fetal CYP2B6 genotype does not significantly impact neonatal exposure29.
2018	Yu Jin et al.	Drug Transporter Genes	Various immune- response drugs	Human Genomes	Genes affecting immune response and drug transport are highly polymorphic, while protein function genes are conserved30.
2015	J.C. Stingl et al.	CYP2D6, CYP2C19	Psychotropic drugs	General Population	CYP2D6 and CYP2C19 polymorphisms explain significant drug metabolism variability, influencing efficacy and safety in psychopharmacological treatments31.
2005	J. Robert et al.	Gene Polymorphisms	Various chemotherapy drugs	Cancer Patients	Gene polymorphisms can help predict drug response and toxicity, improving drug prescription and patient sensitivity outcomes32.
2018	M. Barchitta et al.	Vitamin D Receptor Gene (VDR)	Vitamin D	Pregnant Women	Single nucleotide polymorphisms in the VDR gene affect birth weight and preterm birth risk33.
2019	Inthoun Kulma et al.	ABCB1 (Drug Transporter Gene)	Chemotherapy drugs	Cancer Patients	ABCB1 polymorphisms may predict clinical chemotherapy outcomes, but further research is needed for individualized treatment34.

 

Drug-Drug Interactions and CYP450 Modulation:

During pregnancy, the body experiences profound physiological changes that affect drug metabolism, mainly through the regulation of cytochrome P450 (CYP450) enzymes. Research has indicated that certain CYP enzymes, including CYP3A4 and CYP2D6, undergo increased activity, resulting in increased metabolism of their respective drug substrates. A study by Abduljalil et al. (2020) showed that CYP3A4 activity is increased by around 1.25- fold during the first trimester, 1.75-fold during the second trimester, and 2.32-fold during the third trimester, resulting in the enhanced clearance of drugs such as midazolam⁶. Likewise, Pregnancy induces opposite effects on drug metabolism in which CYP1A2 activity is reduced and that of CYP2D6 and CYP3A increases, impacting dosing changes⁷. In contrast, Pregnancy hormones enhance the clearance of buprenorphine in human hepatocytes by inducing CYP3A4, with the extent of these effects differing among hepatocyte donors. These alterations pose important challenges in drug dosing in pregnancy since some drugs will need dose modification to preserve their therapeutic effects³⁵.

 

The effect of such enzyme changes goes to drug-drug interactions (DDIs), which become increasingly complicated owing to pregnancy-associated enzyme modulation. Alternative CYP3A4 inducers such as phenytoin, phenobarbital, efavirenz, and carbamazepine are contrasted in order to compare their effect on drug metabolism and therapeutic drug concentration, while a CYP2D6 inhibitor such as fluoxetine can decrease drug clearance and enhance the risk of toxicity³⁶. Research by Granfors et al. (2005) concluded that ethinyl estradiol-containing oral contraceptives increased plasma concentrations of tizanidine markedly by inhibiting CYP1A2, a risk further enhanced in pregnancy when CYP1A2 activity is low³⁷. In addition, hormonal changes such as elevated levels of estrogen and progesterone have been revealed in in vitro studies to affect CYP450 enzyme expression and activity further. These synergistic factors necessitate accurate medication management during pregnancy to prevent harmful consequences for the mother and the fetus. Physicians need to closely monitor and regulate drug dosages while taking into account possible DDIs to ensure efficacy and safety³⁷.

 

Fetal Drug Safety And Placental CYP450 Metabolism:

Placental CYP450 Enzymes and Fetal Drug Exposure:

Fetal drug exposure is tightly controlled by the interactions of placental cytochrome P450 (CYP450) enzymes with efflux transporters. The major fetal-specific enzyme CYP3A7 accounts for as much as 50% of total fetal hepatic CYP450 content, and it contributes significantly to metabolism of endogenous steroids and xenobiotics. Li H et al. (2019) indicated that CYP3A7 preferentially metabolizes the sulfate conjugate of dehydroepiandrosterone, an important precursor for estrogen formation during pregnancy, affecting fetal endocrine homeostasis³⁸. Likewise, Chen H et al. (2000) showed that CYP3A7 metabolizes all-trans retinoic acid (atRA), an important compound for fetal development, and this implicates the enzyme in the modulation of teratogenic drug activity³⁹. Furthermore, Blake et al. (2021) found that CYP3A7 is notably involved in metabolizing oxycodone, which points towards its potential implication in opioid in utero exposure. These observations highlight the significance of CYP3A7 in fetal drug burden and exogenous compound susceptibility modulation⁴⁰.

 

Aside from enzymatic metabolism, placental efflux transporters such as P-glycoprotein (P-gp, ABCB1), Breast Cancer Resistance Protein (BCRP, ABCG2), and Multidrug Resistance-associated Protein 1 (MRP1, ABCC1) also have an important protective function by actively ejecting drugs from fetal circulation. Ceckova et al. (2006) illustrated that P-gp greatly limits the placental transfer of antiretroviral drugs, lowering fetal exposure to HIV medications⁴¹.Likewise, Ugele et al. (2003) discovered that BCRP is greatly expressed in the placenta and preferentially transports glyburide, restricting fetal exposure to this anti-diabetic drug (Kozłowska-Rup D., 2011)⁴². Additionally, Granitzer S (2020) emphasized that MRP1 defends placental cells against methyl mercury- induced oxidative stress by exporting the toxic metal and keeping the cells' GSH status in balance⁴³. Nevertheless, maternal differences in CYP450 enzyme activity can change drug metabolism, causing elevated fetal exposure when placental transporters are saturated. These mechanisms together underscore the complexity of fetal drug protection and emphasize the importance of cautious pharmacological considerations during pregnancy.

 

Teratogenicity and Adverse Fetal Outcomes:

Teratogenicity and adverse fetal effects are largely determined by drugs that are metabolized through cytochrome P450 (CYP450) enzymes. Patients with the CYP2C9*2 and CYP2C9*3 gene mutations have decreased mean daily doses of warfarin and an increased risk of bleeding, resulting in fetal warfarin syndrome with nasal hypoplasia and stippled epiphyses⁴⁴. Retinoids like isotretinoin are metabolized by the CYP26 enzymes and have been implicated in craniofacial, cardiac, and central nervous system malformations in cases of its use during pregnancy. Anticonvulsants such as valproic acid, which are CYP2C9 and CYP2A6 metabolized, have also been associated with neural tube defects and congenital malformations⁴⁵.

 

Maternal CYP450 enzyme activity variability may result in unpredictable fetal drug exposure. For example, selective serotonin reuptake inhibitors (SSRIs), which are mainly metabolized by hepatic CYP450 enzymes, have the potential to produce unpredictable drug interactions, from no effect to intoxication. Opioids, metabolized by multiple CYP450 enzymes, have shown an association with higher odds of spontaneous preterm birth (sPTB) among pregnant women. Nonsteroidal anti-inflammatory agents (NSAIDs), CYP2C9-metabolized, used in pregnancy, especially in the third trimester, have been associated with premature closure of the ductus arteriosus and oligohydramnios⁴⁶.

 

Critical periods of susceptibility include fetal development when exposure to teratogenic medications can lead to severe negative results. Organogenesis, between 3rd to 8th weeks of pregnancy, is such a time when the forming fetus is extremely susceptible to teratogens. During this period of exposure to teratogenic drugs, major anatomical abnormalities are caused.

 

Lack of Pharmacokinetic Data in Pregnant Populations:

The limited availability of pharmacokinetic information in pregnant subjects is a problem of complex etiology based on ethical, scientific, and pragmatic difficulties. In the past, pregnant women were deliberately excluded from clinical trials out of concern for fetal safety and future legal responsibilities, creating a considerable knowledge deficit on drug disposition in pregnancy. Such exclusion does hinder the production of evidence-based practice guidelines on medication use among this population⁴⁷.

 

Physiologically Based Pharmacokinetic (PBPK) modeling has become a key tool to overcome this data shortage. PBPK models incorporate physiological alterations during pregnancy, including changed organ dimensions, blood flow rates, and enzyme activity, to forecast drug pharmacokinetics without explicit clinical testing. Szeto KX et al. (2021) were able to create a PBPK model that well simulated the pharmacokinetics of renally cleared drugs such as cefazolin, cefuroxime, and cefradine in various pregnancy phases.⁴⁸ Likewise, Coppola et al. (2022) applied PBPK modeling to predict alterations in drug exposure for renally cleared drugs during pregnancy and gave useful input for clinical decision-making. Such models allow for the prediction of proper dosing regimens, hence promoting drug safety and efficacy for pregnant patients⁴⁹.

 

Despite all these advances, difficulties remain in predicting drug behavior in pregnant females with accuracy. The dynamic physiology of gestation and individual genetic differences make it challenging to model. Additionally, the paucity of available clinical data for validating these models reinforces the call for careful use and interpretation. Thus, although PBPK modeling is a promising method for closing the knowledge gap, continuous efforts to advance these models and include real-world data are crucial to maximize pharmacotherapy in pregnancy.

 

Pharmacogenomic Solutions To Improve Drug Safety In Pregnancy:

Pharmacogenetic Testing and Personalized Dosing:

Pharmacogenetic (PGx) testing, specifically CYP450 genotyping, presents an avenue towards individualized dosing in pregnant women, with the goal of maximizing therapeutic effectiveness and minimizing undesirable outcomes. Emerging pharmacological research also emphasizes the role of precision medicine approaches and pharmacogenomic biomarkers in guiding individualized treatment strategies^71,73,76. The use of PGx testing is sophisticated and involves a multifaceted analysis of multiple factors in this population.

 

Table 2: Pharmacogenomic Solutions to Improve Drug Safety in Pregnancy

Author(s)	Year	Barriers	Drugs Used	Findings
Fatima Suraiya et al.	2023	Limited pharmacogenomic testing awareness	General pregnancy- related medications	Pharmacogenomic testing can enhance medication safety in pregnancy and post- delivery50.
J. Ilekis et al.	2016	Lack of targeted molecular treatments for pregnancy disorders	None (focus on molecular targets)	Molecular targeting in the placenta could lead to new treatments51.
Lauren A. Borda et al.	2023	Pharmacokinetic variability in different regions	Multiple drug interventions	Clinical interventions can help optimize drug use and save time52.
Zoran Todorović et al.	2024	Unreliable antiretroviral drug dosing data	Antiretroviral drugs	More reliable antiretroviral drug dosing data is needed for maternal-fetal safety53.
A. Kammala et al.	2023	Challenges in simulating pregnancy pharmacokinetics	Simulated drug pharmacokinetics	Microfluidic technology can enhance the study of drug pharmacokinetics in pregnancy54.
Dongmei Sun et al.	2020	Variability in drug absorption and elimination	Multiple drug therapies	Drug therapy must consider inter-individual variability in absorption and elimination55.
J. Benevent et al.	2017	Lack of pharmacoepidemiology insights	Various medications for pregnancy safety	Pharmacoepidemiology is essential for evaluating drug safety in pregnancy56.

 

CYP450 Genotyping in Pregnancy: Tailoring Doses for Antidepressants, Pain Medications, and Anticoagulants:

Pregnancy causes physiological changes that affect drug metabolism and may require adjustment of doses. For example, antidepressants like selective serotonin reuptake inhibitors (SSRIs) are metabolized mainly by CYP2D6 and CYP2C19 enzymes. Fabbri et al. (2018) in a study proved CYP2C19 polymorphisms affect the efficacy and side effects of citalopram/escitalopram. This meta-analysis investigated CYP2C19 metabolic phenotypes—poor (PM), intermediate (IM), extensive (EM), and ultra-rapid (UM) metabolizers—in Caucasians. Results from 2558 patients revealed PMs experienced higher symptom improvement (SMD = 0.43) and remission rates (OR = 1.55) than EMs. PMs were at increased risk of gastrointestinal (OR = 1.26), neurological (OR = 1.28), and sexual side effects (OR = 1.52) at weeks 2-4 but not at week 9 or overall side effect burden. PMs were not at greater risk of dropping out, and antidepressant doses were comparable between groups. Although uncommon (~2%), CYP2C19 PMs can inform antidepressant therapy⁵⁷.

 

Likewise, analgesic medications, such as opioids, are metabolized by CYP2D6. CYP2D6 genetic polymorphisms can result in drug metabolism variation, impacting both efficacy and safety. CYP2D6 genotype correlates with opioid analgesia and toxicity, with treatment guidelines for the prescription of codeine and tramadol. On the other hand, poor metabolizers can experience insufficient pain relief⁵⁸. PGx testing can detect such variations, so dose adjustments or alternative therapy may be made.

 

Anticoagulants such as warfarin are metabolized by CYP2C9. CYP2C9 genetic variations may affect warfarin metabolism and thus anticoagulation control and risk of bleeding. PGx testing for CYP2C9 variants can be used to guide warfarin dosing, improving efficacy and safety.

 

Clinical Guidelines and PGx Algorithms for Maternal Pharmacotherapy:

The application of PGx testing in clinical care for pregnant women continues to develop. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines on drug-gene interaction, but definite recommendations for use in pregnant subjects are sparse. Hicks J et al. (2016) pointed out in their study that the 2016 CPIC guideline updates advice on dosing tricyclic antidepressants according to CYP2D6 and CYP2C19 genotypes⁵⁹. These polymorphisms affect exposure, efficacy, and safety of drugs, warranting genotype- driven dosing in order to personalize treatment. Adjustments are recommended for some drugs to reduce side effects and improve therapeutic response.

 

In addition, a study by Liu D et al. (2021) discussed the Pharmacogenomic-guided prescribing may be of benefit to a large number of patients, but future research should overcome barriers and clinical availability of valid pharmacogenomic testing. Nevertheless, the study also indicated that additional research is needed to develop clear guidelines for the use of PGx testing in pregnancy⁶⁰.

 

Advances in Non-Invasive Monitoring of Drug Metabolism:

Developments in non-invasive monitoring methods are transforming our perception of drug metabolism during pregnancy with the promise of safer and more effective therapeutic management of mother and fetus.

 

Liquid Biopsy Strategies: cf DNA and Exosomal RNA:

Liquid biopsy methods, particularly the analysis of circulating cell-free DNA (cfDNA) and exosomal RNA, have emerged as promising tools for monitoring maternal and fetal health.⁶¹ cfDNA, originating from both maternal and fetal tissues, circulates in the maternal bloodstream and can be analyzed to detect genetic variations, including those affecting drug-metabolizing enzymes like cytochrome P450 (CYP450). This non-invasive method permits determination of genetic polymorphisms affecting drug metabolism to enable individualized medication approaches throughout pregnancy. In the same manner, exosomes—tiny extracellular vesicles with RNA—are able to reflect the gene expression patterns of the cells from which they are derived. Examination of exosomal RNA gives insight into the levels of CYP450 enzyme expression and provides a real-time perspective of metabolic function without invasive tissue acquisition. These methods are promising for real-time monitoring of maternal and fetal drug metabolism and will allow clinicians to adjust pharmacotherapy more accurately⁶¹.

 

Real-Time Therapeutic Drug Monitoring (TDM) of High-Risk Drugs:

Real-time therapeutic drug monitoring (TDM) has emerged as a valuable method in maximizing drug therapy, particularly for high-risk drugs. Through the monitoring of drug levels in biological fluids at specified time points, TDM guarantees that drug levels are within the therapeutic window, optimizing efficacy and reducing toxicity. For example, a study by Gatti et al. (2023) illustrated the effectiveness of a real-time TDM-supported expert clinical pharmacological counseling program in the attainment of optimal pharmacokinetic/pharmacodynamic goals with continuous infusion of meropenem in critically ill patients receiving high-intensity continuous veno- venous hemodiafiltration. This strategy resulted in microbiological elimination in the vast majority of situations, demonstrating the potential of real-time TDM to control elaborate drug regimens⁶².

 

In another instance, Alsultan and Peloquin (2014) wrote about the use of TDM in treating tuberculosis, highlighting its application in dosage adjustment according to plasma drug levels to enhance therapeutic effects. They observed that TDM offers clinicians objective data upon which they can base informed decisions regarding dosing, which is especially important in slow-reacting patients⁶³.

 

AI and Machine Learning in Predictive Pharmacogenomics:

Emerging innovations in machine learning (ML) and AI are starting to reshape predictive pharmacogenomics in pregnancy by incorporating large amounts of data—genomic and transcriptomic profiles through clinical and biochemical measurements—to predict outcomes of drug metabolism more accurately. Shan X et al. (2019) created the Network-based Label Space Division approach, namely NLSD-XGB, which efficiently predicts CYP450 enzyme-substrate selectivity in drug metabolism, enhancing drug-drug interactions predictions.⁶⁴ Likewise, Krupp et al. (2020) showed that AI-powered clinical decision support systems (CDSS), which combined real-time therapeutic drug monitoring (TDM) information with pharmacogenomic profiles, significantly minimized adverse drug reactions in high-risk treatments like anticoagulants and opioids in pregnancy by adjusting dosing regimens dynamically⁶⁵. Furthermore, Wu K et al. (2024) presented proof that AI-PBPK modeling can forecast pharmacodynamic effects early in drug discovery, facilitating drug profile alignment with desired effects - considering the dynamic physiological changes during pregnancy, yet also facilitating improved early detection of conditions such as gestational diabetes and preeclampsia, thus extending the reach of predictive pharmacogenomics to maternal-fetal outcomes⁶⁶. Together, these studies highlight the promise of exploiting AI and ML to propel personalized therapy in pregnancy, customizing drug regimens according to unique pharmacogenetic profiles and real-time metabolic tracking to provide safer and more efficacious treatment outcomes.

 

Regulatory Agencies' Role and Policy Implications:

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have also started to include pharmacogenomic issues within their guidelines, highlighting the need for genetic testing to enhance drug safety and efficacy in pregnancy. Green DJ et al. (2021) examined FDA guidance documents and cited that the agency promotes the inclusion of pharmacogenomic biomarkers in clinical trials to have improved understanding of drug exposure and side effects among pregnant populations.[67] In like manner, Jérôme Sainton et al. (2023) evaluated EMA guidelines, observing that the agency advocates for incorporating genetic information—particularly for medications with narrow therapeutic indexes—into risk management strategies among pregnant women. These recommendations are aimed at facilitating individualized dosing and reducing risk to the fetus, but also emphasize the need for ongoing investigation to update these guidelines with newly available data⁶⁸.

 

These advances notwithstanding, some important barriers to the widespread clinical application of pharmacogenomic testing in pregnancy exist. Cost is still a crucial factor; Underhill ML et al. (2017) illustrated that the prohibitively high cost of genetic testing restricts its availability, especially in resource-limited environments⁶⁹. In addition, absence of standardized guidelines and disparity in insurance coverage equally hinder routine application. Furthermore, Giri J et al. (2021) have indicated that inadequate patient education and clinician knowledge about the advantages and limitations of pharmacogenomic testing are among the reasons for reluctance to implement these strategies⁷⁰. These issues highlight the necessity for concerted policy action—such as subsidization of testing, increased educational programs for healthcare providers and patients, and the creation of sound clinical algorithms—to maximize the potential of pharmacogenomics in optimizing drug therapy in mothers and the fetus.

 

Future Directions:

Extension of pharmacogenomic databases to pregnant populations of different diversities is necessary to embrace the entire genetic variability of CYP450 polymorphisms and their effects on drug metabolism. For example, existing pharmacogenomic databases are predominantly biased towards Western populations, which may not capture important genetic variants in other ethnic groups. Their research highlights the need to incorporate multiethnic cohorts to enhance the predictive power of personalized dosing algorithms in obstetric medicine. In addition, the use of a wider range of genomic data could greatly improve risk prediction for drug exposure during pregnancy, and thus maternal and fetal safety.

 

Concurrently, the creation of highly advanced in vitro placental models is an essential research need. Successfully constructing a placental cell culture system that mimics in vivo conditions, allowing for sensitive study of drug metabolism and transplacental drug transfer. Incorporating pharmacogenomic information into these models may further identify the mechanistic basis of maternal-fetal drug disposition. Moreover, importance of genetic counseling and specialized training in obstetric practice to enable the clinical application of PGx-directed therapy. They identified that focused educational programs greatly enhanced clinician confidence and use of pharmacogenomic testing. Lastly, tackling racial and ethnic differences is essential; previous studies noted significant differences in CYP450 allele frequencies between races, highlighting the need for research focused on addressing these differences to promote fair and effective maternal pharmacotherapy. Recent developments in computational pharmacology, chronopharmacology and in-silico drug modeling are expected to further enhance drug discovery and personalized treatment strategies^77-80.

 

CONCLUSION:

The study comprehensively examines the variability of cytochrome P450 (CYP450) enzymes in pregnant women, highlighting its implications for maternal drug metabolism and fetal safety. Physiological changes during pregnancy significantly alter enzyme activity, with CYP3A4 and CYP2D6 upregulation accelerating drug metabolism, while CYP1A2 and CYP2C19 downregulation slows clearance. These variations contribute to inter- individual differences in drug exposure, complicating therapeutic optimization. Genetic polymorphisms in CYP2D6, CYP2C9, and CYP2C19 also influence drug efficacy and safety, especially for opioids, antidepressants, and anticoagulants, and require pharmacogenomic-guided dosing to prevent risks. The study highlights the ethical and logistical challenges of clinical pharmacokinetic research in pregnancy, promoting the use of sophisticated physiologically based pharmacokinetic (PBPK) modeling, liquid biopsy strategies, and AI-powered predictive pharmacogenomics to improve drug safety. Personalized medicine, by genetic screening and therapeutic drug monitoring, is highlighted as an important strategy to maximize drug therapy with minimal fetal toxicity. But the absence of diverse pharmacogenomic data and regulatory issues continue to be challenges to broad clinical application. Closing these gaps through interdisciplinary research and policy integration will be necessary for furthering maternal-fetal pharmacotherapy.

 

LIST OF ABBREVIATIONS:

·       CYP450 – Cytochrome P450

·       PBPK – Physiologically Based Pharmacokinetic

·       TDM – Therapeutic Drug Monitoring

·       SSRIs – Selective Serotonin Reuptake Inhibitors

·       DDIs – Drug-Drug Interactions

·       UMs – Ultra-Rapid Metabolizers

 

REFERENCES:

1.      Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016; 13(11): e1002160. doi: 10.1371/journal.pmed.1002160.

2.      Pinheiro EA, Stika CS. Drugs in pregnancy: Pharmacologic and physiologic changes that affect clinical care. Semin Perinatol. 2020; 44(3):151221. doi: 10.1016/j.semperi.2020.151221

3.      Taschetto APD, Zimath PL, Silvério R, et al. Reduced insulin sensitivity and increased β/α cell mass is associated with reduced hepatic insulin-degrading enzyme activity in pregnant rats. Life Sciences. 2021; 277: 119509. doi: https://doi.org/10.1016/j.lfs.2021.119509.

4.      Hossam Abdelmonem B, Abdelaal NM, Anwer EKE, et al. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines. 2024; 12(7): 1467. Published 2024 Jul 2. doi:10.3390/biomedicines12071467

5.      Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013; 41(2): 256-262. doi:10.1124/dmd.112.050245

6.      Abduljalil K, Pansari A, Jamei M. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. Journal of Pharmacokinetics and Pharmacodynamics. 2020;47(4):361-383. doi: https://doi.org/10.1007/s10928-020-09711-2

7.      Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. American Journal of Obstetrics and Gynecology. 2005; 192(2): 633-639. doi: https://doi.org/10.1016/j.ajog.2004.08.030

8.      Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004;308(3):965-974. doi:10.1124/jpet.103.060137

9.      Cragan JD, Friedman JM, Holmes LB, Uhl K, Green NS, Riley L. Ensuring the Safe and Effective Use of Medications During Pregnancy: Planning and Prevention Through Preconception Care. Maternal and Child Health Journal. 2006; 10(S1): 129-135. doi: https://doi.org/10.1007/s10995-006-0102-2

10.   McCune JS, Lindley C, Decker JL, et al. Lack of Gender Differences and Large Intrasubject Variability in Cytochrome P450 Activity Measured by Phenotyping with Dextromethorphan. The Journal of Clinical Pharmacology. 2001; 41(7): 723-731. doi: https://doi.org/10.1177/00912700122010627

11.   Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p- PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. British Journal of Clinical Pharmacology. 2012; 74(5): 873-885. doi: https://doi.org/10.1111/j.1365-2125.2012.04363.x

12.   Muanda FT, Chaabane S, Boukhris T, et al. Antimalarial drugs for preventing malaria during pregnancy and the risk of low birth weight: a systematic review and meta-analysis of randomized and quasi-randomized trials. BMC Med. 2015; 13:193. Published 2015 Aug 14. doi:10.1186/s12916-015-0429-x

13.   Patoine D, Petit M, Pilote S, Picard F, Drolet B, Simard C. Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes. Pharmacol Res Perspect. 2014; 2(6): e00082. doi:10.1002/prp2.82

14.   Papageorgiou I, Grepper S, Unadkat JD. Induction of Hepatic CYP3A Enzymes by Pregnancy-Related Hormones: Studies in Human Hepatocytes and Hepatic Cell Lines. Drug Metabolism and Disposition. 2012; 41(2): 281-290. doi: https://doi.org/10.1124/dmd.112.049015

15.   Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metabolism and Disposition: The Biological Fate of Chemicals. 2013; 41(2): 263-269. doi: https://doi.org/10.1124/dmd.112.046276

16.   Zhang Y, Wang Z, Wang Y, et al. CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. PeerJ. 2024; 12: e18636. Published 2024 Dec 5. doi:10.7717/peerj.18636

17.   Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clinical Pharmacology and Therapeutics. 1997; 62(4): 400-407. doi: https://doi.org/10.1016/s0009-9236(97)90118-1

18.   Mushtaq M, Ishtiak-Ahmed K, Thirstrup J, Gasse C. Pharmacogenetics and antidepressant treatment outcomes in pregnancy: a Danish-population based study. European Psychiatry. 2022; 65(S1): S104-S104. doi: https://doi.org/10.1192/j.eurpsy.2022.297

19.   Kee PS, Maggo SDS, Kennedy MA, Chin PKL. The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses. Front Pharmacol. 2023; 14: 1080117. Published 2023 Feb 21. doi:10.3389/fphar.2023.1080117

20.   Matic M, Nijenhuis M, Soree B, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2021; 29: 1114-1120. doi:10.1038/s41431- 021-00920-y

21.   Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clinical Pharmacology & Therapeutics. 2011; 91(2): 321-326. doi: https://doi.org/10.1038/clpt.2011.287

22.   Molden E, Jukic MM. CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. Front Pharmacol. 2021; 12: 650750. Published 2021 Apr doi:10.3389/fphar.2021.650750

23.   Badaoui S, Hopkins AM, Rodrigues AD, Miners JO, Sorich MJ, Rowland A. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure. The AAPS Journal. 2021; 23(1). doi: https://doi.org/10.1208/s12248-020-00541-1

24.   Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology. 2001; 52(4): 349-355. doi: https://doi.org/10.1046/j.0306-5251.2001.01499.x

25.   Barten LS, Haslemo T, Jukic MM, et al. A novel CYP2C haplotype associated with ultrarapid metabolism of escitalopram. Clin Pharmacol Ther. 2021; 110(3): 786-795. doi:10.1002/cpt.2233

26.   Qin JB, Luo L, Sun MT, et al. Association between Maternal Drug Use and Cytochrome P450 Genetic Polymorphisms and the Risk of Congenital Heart Defects in Offspring. Biomed Environ Sci. 2022;35(1):45-57. doi:10.3967/bes2022.006

27.   Daud A, Bergman H, Bakker MK, et al. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics. 2014; 15(7): 1029-1041. doi:https://doi.org/10.2217/pgs.14.62

28.   Shea AK, Dong Yao Wang, Snelgrove JW, Dalfen A, Hewko S, Murphy KE. Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications? JOGC/Journal of obstetrics and gynaecology Canada. 2021; 43(6): 726-732. doi: https://doi.org/10.1016/j.jogc.2020.09.026

29.   Eniayewu O, Akinloye A, Shenkoya B, et al. Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype. Pharmacogenet Genomics. 2024; 34(8): 253-260. doi:10.1097/FPC.0000000000000542.

30.   Jin Y, Wang J, Bachtiar M, Chong SS, Lee CGL. Architecture of polymorphisms in the human genome reveals functionally important and positively selected variants in immune response and drug transporter genes. Human Genomics. 2018; 12(1). doi: https://doi.org/10.1186/s40246-018-0175-1

31.   Stingl J, Viviani R. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. Journal of Internal Medicine. 2015; 277(2): 167-177. doi: https://doi.org/10.1111/joim.12317

32.   Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms.

33.   Critical Reviews in Oncology/Hematology. 2005; 54(3): 171-196. doi: https://doi.org/10.1016/j.critrevonc.2005.01.005

34.   Barchitta M, Maugeri A, La Rosa M, et al. Single Nucleotide Polymorphisms in Vitamin D Receptor Gene Affect Birth Weight and the Risk of Preterm Birth: Results From the “Mamma & Bambino” Cohort and A Meta-Analysis. Nutrients. 2018; 10(9): 1172. doi: https://doi.org/10.3390/nu10091172

35.   Kulma I, Boonprasert K, Na-Bangchang K. Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review. Cancer Chemother Pharmacol. 2019; 84(5): 959-975. doi:10.1007/s00280-019-03932-0

36.   Fashe MM, Miner TA, Fallon JK, et al. Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam. Frontiers in Pharmacology. 2023; 14. doi: https://doi.org/10.3389/fphar.2023.1218703

37.   Chen K, Jones HM. PBPK perspective on alternative CYP3A4 inducers for rifampin. CPT Pharmacometrics and Systems Pharmacology. 2022; 11(12): 1543-1546. doi: https://doi.org/10.1002/psp4.12864

38.   Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther. 2005; 78(4): 400-411. doi: 10.1016/j.clpt.2005.06.009

39.   Li H, Lampe JN. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism. Archives of Biochemistry and Biophysics. 2019; 673:108078. doi: https://doi.org/10.1016/j.abb.2019.108078

40.   Chen H, Fantel AG, Juchau MR. Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. Drug Metab Dispos. 2000; 28(9): 1051-1057.

41.   Shum S, Isoherranen N. Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7. AAPS J. 2021; 23(1): 24. Published 2021 Jan 12. doi:10.1208/s12248-020-00537-x

42.   Gedeon C, Behravan J, Koren G, Piquette-Miller M. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006; 27(11-12): 1096-1102. doi: 10.1016/j.placenta.2005.11.012

43.   Kozłowska-Rup D, Czekaj P. Barierowa rola białek nadrodziny ABC w łozysku ludzkim [Barrier role of ABC family of proteins in human placenta]. Ginekol Pol. 2011; 82(1): 56-63.

44.   Granitzer S, Ellinger I, Khan R, et al. In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. Archives of toxicology. 2020; 94(11): 3799-3817. doi: https://doi.org/10.1007/s00204-020-02900-5

45.   Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005; 7(2): 97-104. doi: 10.1097/01.gim.0000153664. 65759.cf

46.   Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci. 2006; 94(2): 261-271. doi:10.1093/toxsci/kfl096

47.   Padilla-Azain MC, Osmundson SS, Bosworth O, et al. Opioid analgesic and antidepressant use during pregnancy and the risk of spontaneous preterm birth: A nested case-control study. Paediatr Perinat Epidemiol. 2025; 39(1): 97-106. doi:10.1111/ppe.13142

48.   Chaphekar N, Dodeja P, Shaik IH, Caritis S, Venkataramanan R. Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. Front Pediatr. 2021; 9: 733823. Published 2021 Nov 3. doi:10.3389/fped.2021.733823

49.   Szeto KX, Le Merdy M, Dupont B, Bolger MB, Lukacova V. PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Kidney in Pregnant Subjects and Fetus. AAPS J. 2021; 23(4): 89. Published 2021 Jun 24. doi:10.1208/s12248-021-00603-y

50.   Dallmann A, Ince I, Solodenko J, et al. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clinical Pharmacokinetics. 2017; 56(12): 1525-1541. doi: https://doi.org/10.1007/s40262-017-0538-0

51.   Suraiya F, Fatima S, Sreevani B, Begum S. Pharmacogenomic in pregnancy. Int J Sci Res. 2023; 12(8): 26-28. doi:10.36106/ijsr/8101145.

52.   Ilekis JV, Tsilou E, Fisher S, et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. American Journal of Obstetrics and Gynecology. 2016; 215(1): S1-S46. doi: https://doi.org/10.1016/j.ajog.2016.03.001

53.   Borda LA, Mats Någård, Boulton DW, Raman Venkataramanan, Coppola P. A systematic review of pregnancy-related clinical intervention of drug regimens due to pharmacokinetic reasons. Frontiers in Medicine. 2023; 10. doi: https://doi.org/10.3389/fmed.2023.1241456

54.   Zoran Todorović, Gordana Dragović, Relja Lukić. Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women. Expert Opinion on Drug Metabolism and Toxicology. 2024; 20(6): 419-437. doi: https://doi.org/10.1080/17425255.2024.2353762

55.   Kammala AK, Richardson LS, Enkhtuya Radnaa, Han A, Menon R. Microfluidic technology and simulation models in studying pharmacokinetics during pregnancy. Frontiers in Pharmacology. 2023; 14. doi: https://doi.org/10.3389/fphar.2023.1241815

56.   Sun D, Hutson JR, Garcia-Bournissen F. Drug therapy during pregnancy. Br J Clin Pharmacol. 2021; 87(4): 1641-1653. doi:10.1111/bcp.14649

57.   Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opinion on Drug Safety. 2017; 16(10): 1181-1190. doi: https://doi.org/10.1080/14740338.2017.1363177

58.   Fabbri C, Tansey KE, Perlis RH, et al. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol. 2018; 28(8): 945-954. doi: 10.1016/j.euroneuro.2018.05.009

59.   Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clinical Pharmacology and Therapeutics. 2021. doi: https://doi.org/10.1002/cpt.2149

60.   Hicks J, Sangkuhl K, Swen J, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clinical Pharmacology and Therapeutics. 2017; 102(1): 37-44. doi: https://doi.org/10.1002/cpt.597

61.   Liu D, Olson KL, Manzi SF, Mandl KD. Patients dispensed medications with actionable pharmacogenomic biomarkers: rates and characteristics. Genetics in Medicine. 2021; 23(4): 782-786. doi: https://doi.org/10.1038/s41436-020-01044-2

62.   Loy C, Ahmann L, De Vlaminck I, Gu W. Liquid Biopsy Based on Cell-Free DNA and RNA. Annual review of Biomedical Engineering. 2024; 26(1): 169-195. doi: https://doi.org/10.1146/annurev-bioeng-110222-111259

63.   Gatti M, Rinaldi M, Cristiana Laici, Siniscalchi A, Viale P, Pea F. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/ Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections. Antibiotics. 2023; 12(11): 1599-1599. doi: https://doi.org/10.3390/antibiotics12111599

64.   Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update [published correction appears in Drugs. 2014 Jun; 74(9): 2061. Dosage error in article text]. Drugs. 2014; 74(8): 839-854. doi:10.1007/s40265-014-0222-8

65.   Shan X, Wang X, Li C, et al. Prediction of CYP450 Enzyme–Substrate Selectivity Based on the Network-Based Label Space Division Method. Journal of Chemical Information and Modeling. 2019; 59(11): 4577-4586. doi: https://doi.org/10.1021/acs.jcim.9b00749

66.   Beregovykh VV, Panteleev VI, Shimanovsky NL. Polypharmacotherapy: the Use of Artificial Intelligence to Reduce Risk of Adverse Drug Reactions (Review). Annals of the Russian academy of medical sciences. 2024; 79(4): 346-352. doi: https://doi.org/10.15690/vramn17965

67.   Wu K, Li X, Zhou Z, et al. Predicting pharmacodynamic effects through early drug discovery with artificial intelligence- physiologically based pharmacokinetic (AI-PBPK) modelling. Frontiers in Pharmacology. 2024; 15. doi: https://doi.org/10.3389/fphar.2024.1330855

68.   Green DJ, Park K, Bhatt-Mehta V, Snyder D, Burckart GJ. Regulatory Considerations for the Mother, Fetus and Neonate in Fetal Pharmacology Modeling. Frontiers in Pediatrics. 2021; 9:698611. doi: https://doi.org/10.3389/fped.2021.698611

69.   Sainton J. Assessment of Comirnaty injections of pregnant women in the manufacturer’s risk management plan and by the European Medicines Agency: mandatory injections for caregivers in France. Int J Vaccine Theory Pract Res. 2023; 3(1): 911-928. doi:10.56098/ijvtpr. v3i1.72

70.   Underhill ML, Blonquist TM, Habin K, et al. A state-wide initiative to promote genetic testing in an underserved population.

71.   Cancer Medicine. 2017; 6(7): 1837-1844. doi: https://doi.org/10.1002/cam4.1100

72.   Giri J, Curry TB, Formea CM, Nicholson WT, Rohrer CR. Education and Knowledge in Pharmacogenomics: Still a Challenge?

73.   Clinical Pharmacology & Therapeutics. 2018; 103(5): 752-755. doi: https://doi.org/10.1002/cpt.1019

74.   Kuhikar N, Duhijod K, Thete M, Channe K. Recent advancements in pharmacogenomic biomarkers for asthma. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 1-6.

75.   Patil AS, Bhatia MS. Pharmacodynamic and pharmacokinetic limitations of anti-protozoal drugs: A comprehensive review. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 15-18.

76.   Singh A, Ahmad S, Singh MK, Kumar B, Afreed. RNA therapeutics: A new era in precision medicine. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 29-34.

77.   Madhuranthagan M, Johnson DB, Jasmine ES, Suresh R, Kumar CS. Cellular and molecular mechanisms contributing to Parkinson’s disease. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 35-45.

78.   Rubina S, Banu Z. Comprehensive insights into obesity: etiology, risk factors, pathophysiology and interventions through in vitro, in vivo and in silico models. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 46-58.

79.   Ahmad W, Khan R, Pathan R, Jain V, Rajput D. Accelerating drug development: the promise of repurposing. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 59-64.

80.   Jakkula R, Banu Z. Experimental models for analgesic, anti-inflammatory and antipyretic activities. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 65-72.

81.   Priya JMK, Venkateswaramurthy N. The role of omega-6 fatty acid in Alzheimer’s disease. Research Journal of Pharmacology and Pharmacodynamics. 2026; 18(1): 73-80.

82.   Bala M, Sapna, Dogra M, Sharma H, Savita. In-silico pharmacology: methods and applications for drug design and discovery.

83.   Research Journal of Pharmacology and Pharmacodynamics. 2025;17(3):235-240.

84.   Kundgir VB, Chandan TR, Patil CD, Bachhav RL, Bhamare MS, Mahajan SK. Drug effects by biological timing: A chronopharmacological perspective. Research Journal of Pharmacology and Pharmacodynamics. 2025;17(4):286-292.

 

Received on 27.03.2026      Revised on 20.04.2026 Accepted on 12.05.2026      Published on 10.07.2026 Available online from July 14, 2026 Res.J. Pharmacology and Pharmacodynamics.2026;18(3):254-264. DOI: 10.52711/2321-5836.2026.00034 ©A and V Publications All right reserved
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.